Delivery Order SPE2DB25D2203-SPE2DB25FPSDZ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for the supply of Humira Pen 40 mg/0.8 mL units. This contract represents a firm fixed price delivery order with an ultimate completion date of July 15, 2025, and was awarded on July 14, 2025 with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $43,110.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with final delivery required by July 15, 2025. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery at its corporate office location. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,108.54 to AmerisourceBergen Drug Corp for the supply of Humira Pen 40 mg/0.8 mL on August 13, 2025, with an ultimate completion date of August 14, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $2,882.06 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mls on May 29, 2025, with a completion date of May 30, 2025. This firm fixed price contract, issued without set-aside designation, represents a competitive award for pharmaceutical supply to support federal medical procurement needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL, a biologic medication commonly used to treat inflammatory conditions. This competitive award, issued on September 4, 2025, with an ultimate completion date of September 5, 2025, represents a firm fixed price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mls on July 21, 2025, with a completion date of July 22, 2025. This firm fixed-price contract represents a non-set-aside competitive award for pharmaceutical supplies to support federal medical procurement needs. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a $1,888.25 delivery order contract to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with an ultimate completion date of August 5, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on May 22, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mls, a biologic medication used to treat inflammatory conditions. This is a firm fixed-price delivery order with a ceiling value of $4,531.80 and an ultimate completion date of May 23, 2025. The contract is non-competitive with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 2, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL with a firm fixed price ceiling value of $9,063.60 and an ultimate completion date of May 5, 2025. This non-set-aside, competitively awarded contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a $3,776.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, with an ultimate completion date of July 23, 2025. This competitive award, issued on July 22, 2025, carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The performance...
- SPE2DB25D2203Indefinite Delivery Contract
- SPE2DB25D2203-SPE2DB25FPSDZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL on August 5, 2025, with an ultimate completion date of August 6, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the place of performance for this contract. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The SPE2DX IDC serves as a comprehensive pharmaceutical and medical supply vehicle supporting military healthcare programs globally, enabling AmerisourceBergen to supply a broad range of products including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. This delivery order for HUMIRA, a biologic medication used primarily for autoimmune conditions, reflects the company's role as a critical pharmaceutical distributor for the Defense Health Agency and other federal healthcare systems. AmerisourceBergen's extensive federal contract portfolio and open competition awards demonstrate its capability to meet rigorous military procurement requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/5/25 |